Organon & Co.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph T. Morrissey Jr.
- Full Time Employees
- 10,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 30 Hudson Street Jersey City NJ United States of America 07302
- IPO Date
- May 14, 2021
- CIK
- 0001821825
- Website
- organon.com
- Similar Companies
- Business
- Organon & Co. is a global pharmaceutical company specializing in developing and delivering health solutions across women's health, biosimilars, and established brands. The company offers a portfolio with more than 70 medicines and devices covering therapeutic areas such as reproductive health (contraception, fertility, maternal health, vaginal health), cardiovascular disease, neurology, dermatology, autoimmune and respiratory conditions. Key products include contraceptives like Nexplanon, hormone replacement therapies, biosimilar medicines, and established brands addressing allergies, dermatology, bone health, and non-opioid pain management. Organon operates internationally, with commercial presence in over 140 markets, including major operations in the United States, Europe, Canada, Japan, and Asia Pacific. It maintains six manufacturing sites in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. Founded in 2021 as a spin-off from Merck & Co., Organon transitioned into an independent publicly traded company headquartered in Jersey City, New Jersey. Recent strategic developments include the acquisition of Forendo Pharma in late 2021 to expand its portfolio with innovative women's health therapies, and the launch of new products such as Emgality and Vtama contributing to established brand growth. In 2024, Organon reported revenue growth driven by portfolio expansion and market penetration, alongside disciplined cost management and efficiency programs targeting $200 million operating savings in 2025. The company emphasizes advancing women's health globally through continuous innovation and targeted therapeutic focus, while adapting to market exclusivity changes and enhancing its biosimilar and established medicine franchises. Organon's main industry segments include pharmaceuticals focused on reproductive medicine, hormone therapies, biosimilars, and established health brands, serving healthcare systems, providers, and patients worldwide. The company's business model integrates product development, manufacturing, and commercialization across diverse geographic regions, leveraging innovative drug-device combinations and broad therapeutic expertise to address unmet medical needs in women's health and beyond. This comprehensive product portfolio and recent strategic investments position Organon as a dedicated health care company aiming to improve patient outcomes through targeted therapies and global market expansion.
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Orogen Royalties Begins Trading on OTCQX Best Market
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
Organon wins US approval to widen use of arthritis biosimilar drug
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know